Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Executive Summary
The Global Biosimilars Market was valued at USD 16.48 Billion in the year 2021 with the Europe region leading the regional market share. One of the main factors driving this market is the expiration of patents of major pharmaceutical drugs and thus the opportunity to develop more biosimilar drugs.
Additionally, Biosimilars are priced way lower than their reference counterparts, with the increasing burden of health expenditure. Biosimilars provide relief to the healthcare infrastructure of several developing countries and are anticipated to impel market growth in the forecast period.
The Asia Pacific is the fastest growing market in the biosimilars market as countries within the region are providing opportunities to grow and sell medicines. The growing initiatives of the government and increasing investment in healthcare are providing rapid growth.
The FDA reported the shortage of drugs during COVID-19 due to a lack of API and disruptions in the supply chain market. The higher rate of competition in the biosimilar market led to the growth of biologics having long-term supplies. A longer time for approvals was occurring due to a delay in the inspection of the manufacturing facility. The delivery of products is also the major concern impacting the market of biosimilars apart from product manufacturing.
Scope of the Report
• The report presents the analysis of Biosimilars Market for the historical period of 2018-2021, estimates for 2022 and the forecast period of 2023-2028.
• The report analyses the Biosimilars Market by Value (USD Million).
• The report analyses the Biosimilars Market by Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin Others).
• The report analyses the Biosimilars Market by Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases, Others).
• The Global Biosimilars Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
• The Global Biosimilars Market has been analysed By Country (United States, Canada, Germany, U.K, France, Italy, Spain, China, Japan, India).
• The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Product Type and by End User.
• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Pfizer, Dr.Reddy's Laboratories, Amgen, Novartis AG, Teva Pharmaceuticals Ltd., Samsung Biologics, Eli lilly and company, Stada Arzneimittel, Celltrion, Biocon Limited.
Key Target Audience
• Biosimilar Companies
• Pharmaceutical and Healthcare Companies
• End Users (Hospitals, Ambulatory Surgical Centres, Research & Laboratories)
• Research and Development (R&D) Organizations
• Government Bodies & Regulating Authorities
• Investment Banks and Equity Firms
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Biosimilars Market: Product Overview
4. Global Biosimilars Market: An Analysis
4.1. Assessment of Macro Economic Indicators of Global Biosimilars Market
4.2 Global Biosimilars Market, Market Size, By Value, 2018-2028
4.3 Global Biosimilars Market: Growth and Forecast
4.4 Impact of COVID-19 on Global Biosimilars Market
5. Global Biosimilars Market: Segment Analysis
5.1 Global Biosimilars Market Segmentation, By Product Type
5.2 Competitive Positioning of Biosimilars Market: By Product Type (2021 & 2028)
5.3 By Monoclonal antibodies, By Value (USD Billion), 2018-2028
5.4 By Filgrastim and Pegfilgrastim, By Value (USD Billion), 2018-2028
5.5 By Insulin, By Value (USD Billion), 2018-2028
5.6 By Others, By Value (USD Billion), 2018-2028
6. Global Biosimilars Market: Segment Analysis By Application
6.1 Global Biosimilars Market Segmentation, By Application
6.2 Competitive Positioning of Global Biosimilars Market, By Application (2021 & 2028)
6.3 By Oncology, By value (USD Billion), 2018-2028
6.4 By Chronic and Autoimmune Diseases, By value (USD Billion), 2018-2028
6.5 By Blood Disorders, By value (USD Billion), 2018-2028
6.6 By Infectious Diseases , By Value (USD Billion), 2018-2028
6.7 By Others, By Value (USD Billion), 2018-2028
7. Global Biosimilars Market: Regional Analysis
7.1 Competitive Positioning of Global Biosimilars Market: By Region (2021 & 2028)
8. Americas Biosimilars Market: An Analysis (2018-2028)
8.1 Assessment of Macro Economic Indicators of Americas Biosimilars Market
8.2 Americas Biosimilars Market- Size and Forecast, By Value (2018-2028)
8.3 Americas Biosimilars Market: Prominent Companies
8.4 Americas Biosimilars Market: Segment Analysis
8.5 Americas Biosimilars Market By Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
8.6 Americas Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others)
8.7 Americas Biosimilars Market: Country Analysis
8.8 Market Opportunity Chart of Americas Biosimilars Market - By Country, By Value (Year-2028)
8.9 Competitive Positioning of Americas Biosimilars Market - By Country
8.10 United States Biosimilars Market: Size and Forecast, By Value (2018-2028)
8.11 United States Biosimilars Market By Product Type and By Application, By Value (2018-2028)
8.12 Canada Biosimilars Market: Size and Forecast, By Value (2018-2028)
8.13 Canada Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9. Europe Biosimilars Market: An Analysis (2018-2028)
9.1 Assessment of Macro Economic Indicators of Asia Pacific Biosimilars Market
9.2 Europe Biosimilars Market- Size and Forecast, By Value (2018-2028)
9.3 Europe Biosimilars Market: Prominent Companies
9.4 Europe Biosimilars Market: Segment Analysis
9.5 Europe Biosimilars Market By Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others), By Value, 2018-2028
9.6 Europe Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value, 2018-2028
9.7 Europe Biosimilars Market: Country Analysis
9.8 Market Opportunity Chart of Europe Biosimilars Market - By Country, By Value (Year-2028)
9.9 Competitive Positioning of Europe Biosimilars Market - By Country
9.10 Germany Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.11 Germany Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.12 United Kingdom Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.13 United Kingdom Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.14 France Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.15 France Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.16 Italy Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.17 Italy Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.18 Spain Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.19 Spain Biosimilars Market By Product Type and By Application, By Value (2018-2028)
10. Asia Pacific Biosimilars Market: An Analysis (2018-2028)
10.1 Assessment of Macro Economic Indicators of Asia Pacific Biosimilars Market
10.2 Asia Pacific Biosimilars Market- Size and Forecast, By Value (2018-2028)
10.3 Asia Pacific Biosimilars Market: Prominent Companies
10.4 Asia Pacific Biosimilars Market: Segment Analysis
10.5 Asia Pacific Biosimilars Market By Product Type, (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
10.6 Asia Pacific Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value
10.7 Asia Pacific Biosimilars Market: Country Analysis
10.8 Market Opportunity Chart of Asia Pacific Biosimilars Market - By Country, By Value (Year-2028)
10.9 Competitive Positioning of Asia Pacific Biosimilars Market - By Country
10.10 China Biosimilars Market: Size and Forecast, By Value (2018-2028)
10.11 China Biosimilars Market By Product Type and By Application, By Value (2018-2028)
10.12 Japan Biosimilars Market: Size and Forecast, By Value (2018-2028)
10.13 Japan Biosimilars Market By Product Type and By Application, By Value (2018-2028)
10.14 India Biosimilars Market: Size and Forecast, By Value (2018-2028)
10.15 India Biosimilars Market By Product Type and By Application, By Value (2018-2028)
11. MEA Biosimilars Market
11.1 Assessment of Macro Economic Indicators of MEA Biosimilars Market
11.2 MEA Biosimilars Market- Size and Forecast, By Value (2018-2028)
11.3 MEA Biosimilars Market By Product Type, (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
11.4 MEA Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value
12. Global Biosimilars Market Dynamics
12.1 Global Biosimilars Market Drivers
12.2 Global Biosimilars Market Restraints
12.3 Global Biosimilars Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness Chart of Global Biosimilars Market - By Product Type (Year 2028)
13.2 Market Attractiveness Chart of Global Biosimilars Market - By Application (Year 2028)
13.3 Market Attractiveness Chart of Global Biosimilars Market - By Region (Year 2028)
14. Competitive Landscape
14.1 Market Share of global leading companies
14.2 Recent Developments and Mergers & Acquisitions
15. Company Profiles (Business Description, Financial Analysis, Business Strategy)
15.1 Pfizer
15.2 Dr.Reddy's Laboratories
15.3 Amgen
15.4 Novartis AG
15.5 Teva Pharmaceuticals Ltd.
15.6 Samsung Biologics
15.7 Eli lilly and company
15.8 Stada Arzneimittel
15.9 Celltrion
15.10 Biocon Limited
Request Sample 
Request Discount 
Inquire Before Buy
